To identify variants that may have resulted from Cas9 treatment, a tumor-normal pipeline was used to call somatic variants that were unique to the AAVS1 treatment (“tumor”) after subtracting the Mock as background (“normal”). Here, PPP1R12C is linked to neoplasm.